ENDO: Fezolinetant Reduces Vasomotor Symptoms in Menopause
Fezolinetant reduces the frequency and severity of moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
Fezolinetant reduces the frequency and severity of moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
Investigators assessed whether low anti-Müllerian hormone levels are associated with bone loss in women experiencing the menopause transition.
Researchers sought to assess the associations of female-specific factors, like age at menopause, with the risk for aneurysmal subarachnoid hemorrhage in women.
Study finds that the timing of natural menopause is significantly affected in women exposed to shift work, especially rotating shift work.
The risk for heart failure is increased with increasing body mass index and waist circumference, especially for those with menopausal age 55 years and older.
A study was conducted to examine the relationship between oral mircobiota, blood pressure, and incident hypertension in postmenopausal women.
About half of postmenopausal women experience female pattern hair loss (FPHL), according to a study published online.
Endometriosis can potentially lead to pelvic pain and a number of complications. What does research say about whether endometriosis can be related to early natural menopause?
The link between menopause and changes in cognitive function is a subject of debate. Researchers sought to investigate the potential association with the aim of improving womens’ health.
Prediabetes can put postmenopausal women at risk for cardiovascular diseases, metabolic disorders, and osteoporosis. Investigators sought to determine the effect of bisphosphonates’ effect (such as alendronate) on lipid profiles.